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To identify prognostic factors for survival and risk classification in Japanese patients, we studied clinical
parameters in 79 patients with metastatic renal cell carcinoma (mRCC) treated at our institution from 1988 to
2004. Univariate and multivariate analyses were performed to identify prognostic factors for survival. In
univariate analysis, the absence of nephrectomy, metastasis at first visit, ECOG performance status (PS) 2 or
more, liver metastasis, brain metastasis, low hemoglobin (＜lower limit of normal), C-reactive protein (CRP)
＞0.3, and serum lactate dehydrogenase (LDH) higher than 1.5 times the upper normal limit were
significantly associated with poor outcome. Multivariate analysis demonstrated that two variables remained
significant : hepatic metastasis and high LDH. Hepatic metastasis, high LDH, nephrectomy, metastasis at first
visit, poor ECOG PS and CRP ＞0.3 were used to categorize patients into three groups. The 2-year
survival rate was 72.9% for the patients with no or one risk factor, 40.2% for those with two and 15.1% for
those with three or more. According to Motzer’s criteria, the 2-year survival rates for patients with favorable
risk, intermediate risk, and poor risk were 85.1, 33.0, and 13.1％ respectively. Our prognostic criteria are
simple, and can be used to categorize Japanese patients with mRCC into three risk groups.
(Hinyokika Kiyo 56 : 75-79, 2010)


















* 現 : 函館五稜郭病院泌尿器科
性について本症例を用いて検証した．









例 hazard model による多変量解析を行った．これら
の解析の結果を基に予後分類を試みた．全生存率は






Karnofsky Performance status (PS) ＜80，3）ヘモグロ




れぞれ予後良好 (favorable-risk) 群，予後中間 (inter-
mediate-risk) 群，予後不良 (poor-risk) 群としこれら
の生存率を算出した．
結 果




































































































































HR 95％ CI P-value
ECOG performance status 2.00 0.96-4.18 0.064
腎摘出術 1.56 0.78-3.14 0.21
初診時転移 1.58 0.75-3.31 0.23
肝転移 3.20 1.48-6.91 0.0031
脳転移 1.60 0.61-4.19 0.34
ヘモグロビン値 1.46 0.77-2.76 0.24
LDH 3.05 1.30-7.16 0.010





Fig. 3. Motzer 分類による全生存率.





発現は hypoxia-inducible factor 1a (HIF-1a) を介してい
ることが判明している12,13)．HIF-1a は腫瘍血管新生
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